X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (179679) 179679
Publication (10355) 10355
Book Review (789) 789
Book Chapter (182) 182
Conference Proceeding (163) 163
Magazine Article (144) 144
Book / eBook (101) 101
Dissertation (58) 58
Newsletter (26) 26
Web Resource (25) 25
Data Set (13) 13
Trade Publication Article (8) 8
Presentation (5) 5
Reference (5) 5
Government Document (4) 4
Newspaper Article (4) 4
Paper (4) 4
Patent (2) 2
Report (2) 2
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (172553) 172553
female (110229) 110229
antineoplastic combined chemotherapy protocols - therapeutic use (104761) 104761
male (91838) 91838
middle aged (84829) 84829
oncology (77596) 77596
adult (70865) 70865
aged (68924) 68924
combined modality therapy (64212) 64212
index medicus (60267) 60267
chemotherapy (46947) 46947
treatment outcome (42349) 42349
cancer (35594) 35594
antineoplastic combined chemotherapy protocols - adverse effects (30325) 30325
prognosis (29992) 29992
neoplasm staging (27266) 27266
antineoplastic combined chemotherapy protocols - administration & dosage (21297) 21297
survival rate (21155) 21155
retrospective studies (21048) 21048
aged, 80 and over (20646) 20646
cisplatin - administration & dosage (20386) 20386
adolescent (20093) 20093
follow-up studies (18453) 18453
surgery (17970) 17970
hematology (17947) 17947
disease-free survival (17657) 17657
radiotherapy (17257) 17257
therapy (16668) 16668
care and treatment (16159) 16159
survival analysis (16107) 16107
fluorouracil - administration & dosage (16010) 16010
chemotherapy, adjuvant (15744) 15744
survival (15187) 15187
doxorubicin - administration & dosage (14560) 14560
cyclophosphamide - administration & dosage (14221) 14221
child (14165) 14165
breast neoplasms - drug therapy (14141) 14141
animals (13588) 13588
antineoplastic agents - therapeutic use (13543) 13543
lung neoplasms - drug therapy (13241) 13241
drug administration schedule (13061) 13061
carcinoma (12283) 12283
cisplatin (12180) 12180
medicine & public health (11837) 11837
remission induction (11704) 11704
time factors (10108) 10108
vincristine - administration & dosage (10079) 10079
child, preschool (9884) 9884
trial (9453) 9453
tumors (9308) 9308
research (9175) 9175
breast neoplasms - pathology (9068) 9068
prospective studies (9009) 9009
breast cancer (8801) 8801
hematology, oncology and palliative medicine (8699) 8699
analysis (8669) 8669
young adult (8279) 8279
mice (8254) 8254
risk factors (8230) 8230
etoposide - administration & dosage (8095) 8095
neoplasm metastasis (8015) 8015
clinical trials as topic (8010) 8010
deoxycytidine - analogs & derivatives (7980) 7980
metastasis (7903) 7903
dose-response relationship, drug (7841) 7841
health aspects (7758) 7758
adenocarcinoma - drug therapy (7533) 7533
carcinoma, non-small-cell lung - drug therapy (7526) 7526
recurrence (7515) 7515
paclitaxel - administration & dosage (7445) 7445
antineoplastic agents - administration & dosage (7334) 7334
antineoplastic combined chemotherapy protocols - pharmacology (7271) 7271
pharmacology & pharmacy (7125) 7125
radiation-therapy (6883) 6883
lung neoplasms - pathology (6855) 6855
lymphatic metastasis (6788) 6788
neoadjuvant therapy (6623) 6623
carboplatin - administration & dosage (6603) 6603
infant (6539) 6539
deoxycytidine - administration & dosage (6509) 6509
radiotherapy dosage (6493) 6493
methotrexate - administration & dosage (6459) 6459
cell line, tumor (6427) 6427
antineoplastic combined chemotherapy protocols (6413) 6413
tomography, x-ray computed (6258) 6258
radiology, nuclear medicine & medical imaging (6233) 6233
disease progression (6085) 6085
drug therapy (5992) 5992
combination (5921) 5921
kaplan-meier estimate (5904) 5904
paclitaxel (5871) 5871
prednisone - administration & dosage (5773) 5773
fluorouracil (5760) 5760
cyclophosphamide (5751) 5751
ovarian neoplasms - drug therapy (5721) 5721
carcinoma, squamous cell - drug therapy (5713) 5713
radiotherapy, adjuvant (5654) 5654
phase-ii (5585) 5585
neoplasms - drug therapy (5527) 5527
colorectal neoplasms - drug therapy (5513) 5513
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (60) 60
Online Resources - Online (23) 23
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
UofT at Mississauga - Stacks (2) 2
Humber River Regional Hospital - Church Stacks (1) 1
OISE - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Online (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (158340) 158340
Japanese (11174) 11174
German (4006) 4006
French (3546) 3546
Chinese (2753) 2753
Russian (1592) 1592
Spanish (1183) 1183
Italian (853) 853
Polish (717) 717
Hungarian (311) 311
Dutch (212) 212
Czech (176) 176
Portuguese (106) 106
Danish (95) 95
Korean (82) 82
Romanian (76) 76
Hebrew (73) 73
Ukrainian (69) 69
Bulgarian (58) 58
Norwegian (53) 53
Serbian (52) 52
Finnish (47) 47
Turkish (38) 38
Croatian (34) 34
Swedish (22) 22
Lithuanian (19) 19
Slovak (16) 16
Bosnian (10) 10
Afrikaans (4) 4
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2010, Volume 119, Issue 2, pp. 212 - 216
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
JAMA, ISSN 0098-7484, 11/2016, Volume 316, Issue 18, pp. 1888 - 1896
IMPORTANCE: Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and... 
MEDICINE, GENERAL & INTERNAL | FOLLOW-UP | THERAPY | EUROPEAN-ORGANIZATION | CMF | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Epirubicin - administration & dosage | Austria | Sweden | Fluorouracil - administration & dosage | Antineoplastic Agents - adverse effects | Chemotherapy, Adjuvant - adverse effects | Adult | Female | Drug Administration Schedule | Neoplasm Recurrence, Local | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Quality of Life | Breast Neoplasms - mortality | Aged | Germany | Women | Chemotherapy | Usage | Adjuvant treatment | Clinical trials | Breast cancer | Diagnosis | Research | Comparative analysis | Health aspects | Cancer | Womens health | Risk factors | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 19, pp. 3138 - 3145
Journal Article
by Wasan, Harpreet and Wasan, Harpreet S and Gibbs, Peter and Sharma, Navesh K and Sharma, Navesh and Sharma, Ricky A and Taieb, Julien and Heinemann, Volker and Ricke, Jens and Peeters, Marc and Findlay, Michael and Weaver, Andrew and Mills, Jamie and Wilson, Charles and Wilson, Greg and Adams, Richard and Francis, Anne and Moschandreas, Joanna and Virdee, Pradeep S and Dutton, Peter and Love, Sharon and Gebski, Val and Gray, Alastair and Bateman, Andrew and Blesing, Claire and Brown, Ewan and Brown, Michael and Chau, Ian and Cummins, Sebastian and Cunningham, David and Falk, Stephen and Hadaki, Maher and Hall, Marcia and Hickish, Tamas and Hornbuckle, Joanne and Lofts, Fiona and Lowndes, Sarah and Mayer, Astrid and Metcalfe, Matthew and Middleton, Gary and Montazeri, Amir and Muirhead, Rebecca and Polychronis, Andreas and Purcell, Colin and Ross, Paul and Sherwin, Liz and Smith, Randall and Smith, David and Smith, Denis and Soomal, Rubin and Swinson, Daniel and Walther, Axel and Amin, Pradip and Angelelli, Bruna and Balosso, Jacques and Beny, Alex and Bloomgarden, Daniel and Boucher, Evelyn and Bruch, Harald-Robert and Bui, James and Burge, Matthew and Burge, Mathew and Cardaci, Giuseppe and Carlisle, James and Chai, Seungjean and Chen, Yi-Jen and Chevallier, Patrick and Chuong, Michael and Clarke, Stephen and Coveler, Andrew and Craninx, Michael and Delanoit, Thierry and Deleporte, Amelie and Deleporte, Amélie and Eliadis, Paul and Facchini, Francis and Ferguson, Tom and Ferguson, Thomas and Ferrante, Michel and Frenette, Gary and Frick, Jacob and Ganju, Vinod and Garofalo, Michael and Geboes, Karen and Gehbauer, Gerald and George, Benjamin and Geva, Ravit and Gordon, Michael and Gregory, Kate and Gulec, Seza and Hannigan, James and van Hazel, Guy and Heching, Norman and Helmberger, Thomas and Hendlisz, Alain and Hendrickx, Koen and Holtzman, Matthew and Isaacs, Richard and Jackson, Christopher and James, Philip and ... and FOXFIRE Trial Investigators and FOXFIRE-Global Trial Investigators and SIRFLOX Trial Investigators and SIRFLOX trial investigators and FOXFIRE trial investigators and FOXFIRE-Global trial investigators
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. 1159 - 1171
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Journal Article